Abstract
* Eribulin mesylate (Halaven), a microtubule inhibitor, has been approved for the treatment of late-stage, metastatic breast cancer after other treatments have failed.
* Eribulin mesylate was found to prolong life in women with late-stage breast cancer.
* The drug can prolong the QT interval and shouldn't be given in combination with other drugs that do so.